BR112018073178A2 - método, matriz e uso dos mesmos - Google Patents

método, matriz e uso dos mesmos

Info

Publication number
BR112018073178A2
BR112018073178A2 BR112018073178-1A BR112018073178A BR112018073178A2 BR 112018073178 A2 BR112018073178 A2 BR 112018073178A2 BR 112018073178 A BR112018073178 A BR 112018073178A BR 112018073178 A2 BR112018073178 A2 BR 112018073178A2
Authority
BR
Brazil
Prior art keywords
pancreatic cancer
determining
test sample
associated disease
methods
Prior art date
Application number
BR112018073178-1A
Other languages
English (en)
Inventor
Borrebaeck Carl
Sandström Gerdtsson Anna
Wingren Christer
Original Assignee
Immunovia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovia Ab filed Critical Immunovia Ab
Publication of BR112018073178A2 publication Critical patent/BR112018073178A2/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/5436—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand physically entrapped within the solid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366—Apparatus specially adapted for solid-phase testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/563—Immunoassay; Biospecific binding assay; Materials therefor involving antibody fragments
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

a presente invenção fornece um método para diagnosticar ou determinar um estado de doença associada ao câncer pancreático que compreende ou consiste nas etapas de: (a) fornecer uma amostra de um indivíduo a ser testada; e (b) determinar uma assinatura de biomarcador da amostra de teste medindo-se a presença e/ou quantidade na amostra de teste de um ou mais biomarcadores selecionados a partir do grupo definido na tabela a; em que a presença e/ou quantidade na amostra de teste do um ou mais biomarcadores selecionados a partir do grupo definido na tabela a é indicativa da doença associada ao câncer pancreático no indivíduo; usos e métodos para determinar um estado de doença associada ao câncer pancreático e métodos para tratar câncer pancreático, juntamente com matrizes e kits para uso no mesmo.
BR112018073178-1A 2016-05-10 2017-05-10 método, matriz e uso dos mesmos BR112018073178A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1608192.9A GB201608192D0 (en) 2016-05-10 2016-05-10 Method, array and use thereof
GB1608192.9 2016-05-10
PCT/EP2017/061202 WO2017194613A2 (en) 2016-05-10 2017-05-10 Method, array and use thereof

Publications (1)

Publication Number Publication Date
BR112018073178A2 true BR112018073178A2 (pt) 2019-02-19

Family

ID=56297465

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018073178-1A BR112018073178A2 (pt) 2016-05-10 2017-05-10 método, matriz e uso dos mesmos

Country Status (13)

Country Link
US (2) US20200011872A1 (pt)
EP (2) EP3907509A3 (pt)
JP (2) JP2019516981A (pt)
KR (1) KR20190005858A (pt)
CN (1) CN109564221A (pt)
AU (1) AU2017261762A1 (pt)
BR (1) BR112018073178A2 (pt)
CA (1) CA3022022A1 (pt)
GB (1) GB201608192D0 (pt)
IL (1) IL262824A (pt)
MX (1) MX2018013621A (pt)
RU (1) RU2018138639A (pt)
WO (1) WO2017194613A2 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100105571A1 (en) 2007-03-27 2010-04-29 Carl Arne Krister Borrebaeck Protein Signature/Markers for the Detection of Adenocarcinoma
SG11201909949XA (en) 2017-05-24 2019-11-28 Pandion Therapeutics Inc Targeted immunotolerance
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
GB202010970D0 (en) 2020-07-16 2020-09-02 Immunovia Ab Methods, arrays and uses thereof
WO2022109105A1 (en) * 2020-11-18 2022-05-27 Pandion Operations, Inc. Madcam targeted therapeutics and uses thereof
WO2022204332A1 (en) * 2021-03-24 2022-09-29 Combangio, Inc. Compositions comprising c-met agonist antibodies and methods for use in ocular treatment

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3169789D1 (en) 1980-05-02 1985-05-15 Edward P Davis Leg aid device
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4486530A (en) 1980-08-04 1984-12-04 Hybritech Incorporated Immunometric assays using monoclonal antibodies
US5856090A (en) 1994-09-09 1999-01-05 The Scripps Research Institute DNA-methylase linking reaction
GB9703369D0 (en) 1997-02-18 1997-04-09 Lindqvist Bjorn H Process
US7429452B2 (en) * 2002-10-31 2008-09-30 Hoffmann-La Roche Inc. Methods for diagnosis and therapy of pancreatic cancer and composition useful therein
US9005613B2 (en) * 2003-06-16 2015-04-14 Immunomedics, Inc. Anti-mucin antibodies for early detection and treatment of pancreatic cancer
WO2007013360A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Pancreatic cancer related gene cst6 and gabrp
US20100105571A1 (en) * 2007-03-27 2010-04-29 Carl Arne Krister Borrebaeck Protein Signature/Markers for the Detection of Adenocarcinoma
JP5931874B2 (ja) * 2010-08-13 2016-06-08 ソマロジック・インコーポレーテッド 膵癌バイオマーカーおよびその使用
GB201103726D0 (en) * 2011-03-04 2011-04-20 Immunovia Ab Method, array and use thereof
WO2013052480A1 (en) * 2011-10-03 2013-04-11 The Board Of Regents Of The University Of Texas System Marker-based prognostic risk score in colon cancer
WO2013106844A2 (en) * 2012-01-13 2013-07-18 Oncocyte Corporation Methods and compositions for the treatment and diaginosis of pancreatic cancer
KR20140094180A (ko) * 2013-01-21 2014-07-30 연세대학교 산학협력단 보체인자 b 단백질에 특이적으로 결합하는 폴리펩타이드 또는 항체를 포함하는 췌장암 진단용 조성물
WO2014160499A2 (en) * 2013-03-13 2014-10-02 Creatics Llc Methods and compositions for detecting pancreatic cancer
US20160055297A1 (en) * 2013-04-17 2016-02-25 Lg Electronics Inc. Method for extracting biomarker for diagnosing pancreatic cancer, computing device therefor, biomarker for diagnosing pancreatic cancer and device for diagnosing pancreatic cancer including the same
RU2693006C2 (ru) * 2013-10-01 2019-07-01 Торэй Индастриз, Инк. Способ выявления опухоли поджелудочной железы, антитела и набор для выявления опухоли поджелудочной железы
GB201319878D0 (en) * 2013-11-11 2013-12-25 Immunovia Ab Method, Array and use thereof
US10451628B2 (en) * 2014-05-07 2019-10-22 University Of Utah Research Foundation Biomarkers and methods for diagnosis of early stage pancreatic ductal adenocarcinoma
KR20150129932A (ko) * 2014-05-12 2015-11-23 연세대학교 산학협력단 보체인자 b 단백질에 특이적으로 결합하는 항체를 포함하는 췌장암 진단용 키트
CN105092845A (zh) * 2015-07-10 2015-11-25 深圳市贝沃德克生物技术研究院有限公司 胰腺癌蛋白生物标记物、用途及其检测芯片和检测装置
GB201516801D0 (en) * 2015-09-22 2015-11-04 Immunovia Ab Method, array and use thereof

Also Published As

Publication number Publication date
GB201608192D0 (en) 2016-06-22
AU2017261762A1 (en) 2018-11-15
JP2019516981A (ja) 2019-06-20
EP3907509A3 (en) 2021-12-29
KR20190005858A (ko) 2019-01-16
MX2018013621A (es) 2019-04-25
IL262824A (en) 2018-12-31
EP3907509A2 (en) 2021-11-10
CA3022022A1 (en) 2017-11-16
RU2018138639A3 (pt) 2020-10-30
CN109564221A (zh) 2019-04-02
JP2021165745A (ja) 2021-10-14
RU2018138639A (ru) 2020-06-10
WO2017194613A2 (en) 2017-11-16
WO2017194613A3 (en) 2017-12-21
EP3455632A2 (en) 2019-03-20
US20220206004A1 (en) 2022-06-30
US20200011872A1 (en) 2020-01-09

Similar Documents

Publication Publication Date Title
BR112018073178A2 (pt) método, matriz e uso dos mesmos
BR112016010510A2 (pt) método, arranjo e uso do mesmo
MX2019008911A (es) Metodos, matrices y usos de estos.
BR122019023720A8 (pt) Kit de triagem de um indivíduo em uma população por meio de avaliação ou prognóstico do risco de um evento cardiovascular futuro dentro de um período de 5 anos
BR112013003391A2 (pt) biomarcadores de câncer pancreático e usos dos mesmos
WO2017050939A3 (en) Method and array for diagnosing pancreatic cancer in an individual
BR112018017168A2 (pt) emplastro de coloração do sangue, método e dispositivo para teste sanguíneo usando o mesmo
BR112015023120A2 (pt) método para identificar um indivíduo com uma doença ou disfunção, método para prever a responsividade de um indivíduo com uma doença ou disfunção, método para determinar a probabilidade de que um indivíduo com uma doença ou disfunção exibirá benefício do tratamento, método para selecionar uma terapia, usos de um antagonista de ligação do eixo pd-l1, ensaio para identificar um indivíduo com uma doença, kit de diagnóstico, método para avaliar uma resposta ao tratamento e método para monitorar a resposta de um indivíduo tratado
AR095363A1 (es) Biomarcadores y métodos para el tratamiento de condiciones relacionadas con pd-1 y pd-l1
BR112017025051A2 (pt) ensaio celular para detecção de homodímeros anti-cd3
BR112016019836A2 (pt) método para analisar uma amostra de um sujeito, dispositivo de diagnóstico para utilização no diagnóstico da endometriose, kit, uso de um biomarcador, e, método para aumentar uma resposta de anticorpos em um sujeito
BR112014011818A2 (pt) método para realizar ensaios de quantificação
MY192493A (en) Urinalysis device and dry reagent for quantitative urinalysis
BR112017004773A2 (pt) biomarcadores para avaliar câncer de mama
MX363201B (es) Procedimiento, matriz y uso para determinar la presencia de cancer pancreatico.
BR112016018044A2 (pt) teste de diagnóstico molecular para prever resposta às drogas antiangiogênicas e prognóstico de câncer
BR112014006432A2 (pt) biomarcadores do câncer de pulmão e seus usos
BR112014030298A8 (pt) Métodos e kits destinados para ensaios baseados em aptâmeros multiplexados
BR112014026582A2 (pt) método para identificar agentes capazes de induzir a sensibilização respiratória e matriz e kits analíticos para uso no método
BR112016028534A2 (pt) ceramidas e seu uso em diagnosticar cvd
BR112017011026A2 (pt) métodos analíticos e arranjos para uso nos mesmos
BR112017021767A2 (pt) sistema e método para triagem de alta produtividade de células cancerosas
BR112017006315A2 (pt) agente terapêutico, uso de um agente terapêutico, métodos in vitro para determinar se um sujeito com melanoma tem um risco maior de desenvolver metástase, de determinação de um regime de tratamento para um sujeito que sofre de melanoma, de tratamento de um sujeito que sofre de melanoma, ensaio in vitro para predizer o risco aumentado de metástase e kits
BR112014029233A8 (pt) método para diagnosticar se um indivíduo grávido não está em risco, usos de pelo menos um dos biomarcadores sfit-1, endoglina e pigf, dispositivo, kit, método de gestão de um indivíduo, sistema e método para estabelecer um auxílio
WO2015189591A3 (en) Method and arrays for use in diagnosing early breast cancer

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2670 DE 08-03-2022 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.